Efficacy of EGFR monoclonal antibody combined with chemotherapy in treatment of 245 patients with advanced head and neck squamous cell carcinoma

doi:10.19438/j.cjoms.2019.02.006

Abstract

Abstract: PURPOSE: To study the efficacy and safety of epidermal growth factor receptor(EGFR) monoclonal antibody in the treatment of advanced head and neck squamous cell carcinoma. METHODS: Two hundred and forty-five patients with advanced (stage III-IV) head and neck squamous cell carcinoma were selected from May 2008 to December 2017. They were divided into primary group (n=152) and relapse group (n=93). Both groups received platinum-based chemotherapy combined with EGFR monoclonal antibody 100-200 mg per intravenous drip. The safety and efficacy of the treatment were analyzed. SPSS 17.0 software package was used for statistical analysis. RESULTS: After treatment, the total effective rate was 81.0% in 42 patients with primary oropharyngeal cancer and 45.4% in 110 patients with primary oral cancer, 44.4% in 9 patients with recurrent oropharyngeal cancer and 27.4% in 84 patients with recurrent oral cancer. The median survival time was 57 months in the primary group and 8 months in the relapse group. After five years of treatment, the overall survival rate was 47.7% in the primary group and 8.0% in the relapse group. Skin rash was the main side effect of EGFR mAb, but the incidence was only 1.63%. CONCLUSIONS: EGFR monoclonal antibody combined with platinum-based chemotherapy for advanced head and neck squamous cell carcinoma has a higher effective rate and survival rate than chemotherapy alone, and the analgesic effect is remarkable, which creates a better treatment opportunity for subsequent treatment such as surgery, and can effectively improve the quality of life of patients, and does not increase serious adverse reactions of chemotherapy.

Key words: EGFR monoclonal antibody, Head and neck, Squamous cell carcinoma, Advanced stage

CLC Number:

R739.8

WANG Hong, WU Yun-teng, MA Xu-hui, GUO Wei, REN Guo-xin. Efficacy of EGFR monoclonal antibody combined with chemotherapy in treatment of 245 patients with advanced head and neck squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(2): 129-133.

References

[1] Stewart BW, Kleihues P.World cancer report [R]. Geneva: International Agency for Research on Cancer, 2003: 506-507.
[2] Mountzios G.Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy[J]. World J Clin Oncol, 2015, 6(1): 7-15.
[3] Spector JG, Sessions DG, Chao KS, et al.Management of stage Ⅱ (T2N0M0) glottic carcinoma by radiotherapy and conservation surgery[J]. Head Neck, 1999, 21(2): 116-123.
[4] Sessions DG, Lenox J, Spector GJ.Supraglottic laryngeal cancer: analysis of treatment results[J]. Laryngoscope, 2010, 115(8): 1402-1410.
[5] Seiwert TY, Cohen EE.State-of-the-art management of locally advanced head and neck cancer[J]. Br J Cancer, 2005, 92(8): 1341-1348.
[6] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[7] Posner MR, Haddad RI, Wirth L, et al.Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach[J]. Semin Oncol, 2004, 31(6):778-785.
[8] Lefebvre JL, Chevalier D, Luboinski B, et al.Larynx preservation in pyriform sinus cancer: preliminary results of a european organization for research and treatment of cancer phase Ⅲ trial[J]. J Natl Cancer Inst, 1996, 88(13): 890-899.
[9] 郭伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 口腔颌面外科杂志, 2012, 22(2): 77-81.
[10] Busch CJ, Tribius S, Schafhausen P, et al.The current role of systemic chemotherapy in the primary treatment of head and neck cancer[J]. Cancer Treat Rev, 2015, 41(3): 217-221.
[11] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[12] Mathers CD, Shibuya K, Boschi-Pinto C et al. Global and regional estimates of cancer mortality and incidence by site : I. Application of regional cancer survival model to estimate cancer mortality distribution by site[J]. BMC Cancer, 2002, 2: 36.
[13] Parkin DM, Bray F, Ferlay J, et al.Global cancer statistics, 2002[J]. CA A Cancer J Clin, 2005, 55(2): 74-108.
[14] Lamont EB, Vokes EE.Chemotherapy in the management of squamous-cell carcinoma of the head and neck[J]. Lancet Oncol, 2001, 2(5): 261-269.
[15] Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5): 343-349.
[16] Cohen EE.Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2006, 24(17): 2659-2665.
[17] Kameswaran M, Samuel G, Dev Sarma H, et al.¹³¹I-Nimotuzumab-A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR[J]. Appl Radiat Isot, 2015, 102: 98-102.
[18] Vermorken JB, Specenier P.Optimal treatment for recurrent/metastatic head and neck cancer[J]. Ann Oncol, 2010, 21(Suppl 7): 252-261.
[19] Bonner JA, Harari PM, Giralt J, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6): 567-578.
[20] Vermorken JB, Mesia R, Rivera F, et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11): 1116-1127.
[21] Vermorken JB, Trigo J, Hitt R, et al.Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J]. J Clin Oncol, 2007, 25(16): 2171-2177.
[22] Sundvall M, Karrila A, Nordberg J, et al.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma[J]. Expert Opin Emerg Drugs, 2010, 15(2): 185-201.
[23] Basavaraj C, Sierra P, Shivu J, et al.Nimotuzumab with chemoradiation confers a survival advantage in treatment-na?ve head and neck tumors over expressing EGFR[J]. Cancer Biol Ther, 2010, 10(7): 673-681.
[24] Xu S, Ramos-Suzarte M, Bai X, et al.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience[J]. Oncotarget, 2016, 7(22): 33391-33407.
[25] Ledón N, Casacó A, Casanova E, et al.Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models[J]. Placenta, 2011, 32(7): 531-534.
[26] Rojo F, Gracias E, Villena N, et al.Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study[J]. Clin Cancer Res, 2010, 16(8): 2474-2482.